title: Corticotropin-releasing factor receptor type I mediates stress-induced relapse to opiate dependence in rats.
abstract: The possible effect of different corticotropin-releasing factor receptor (CRFR) antagonists (alpha-helical CRF, CP-154,526 and AS-30) on the maintenance and reactivation of morphine-conditioned place preference (CPP) induced by morphine or footshock stress, respectively, were investigated in rats. The results show that morphine-induced maintenance of CPP was not affected by pretreatment with any CRFR antagonists. However, morphine-induced the reactivation of CPP was significantly attenuated by pre-administration of 10 microg alpha-helical CRF (i.c.v.). The maintenance of morphine CPP could be induced by repeated footshock and this effect was significantly attenuated by pretreatment of 10 microg alpha-helical CRF (i.c.v.) and 10 mg CP-154,526 (i.p.). Furthermore, following a 28-day extinction of morphine CPP, a single footshock could again elicit the reactivation of place preference that was blocked by pretreatment with 10 microg alpha-helical CRF (i.c.v.) and 1 or 10 mg CP-154,526 (i.p.). The present study demonstrates that CRFR type 1, but not CRFR type 2, mediates the stress-induced maintenance and reactivation of morphine CPP. These findings suggest that CRFR type 1 antagonists might be of some value in the treatment and prevention of stress-induced relapse to drug dependence long after detoxification.
authors.affiliation: National Laboratory of Medical Neurobiology, Shanghai Medical University, P.R.China.
authors.forename: L
authors.initials: L
authors.lastname: Lu
authors.forename: X
authors.initials: X
authors.lastname: Ceng
authors.forename: M
authors.initials: M
authors.lastname: Huang
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects / Q000502:physiology; D003213:Conditioning, Psychological / Q000187:drug effects / Q000502:physiology; D003346:Corticotropin-Releasing Hormone / Q000378:metabolism / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions / Q000502:physiology; D004558:Electric Stimulation / Q000009:adverse effects; D008297:Male; D009020:Morphine / Q000494:pharmacology; D009483:Neuropsychological Tests; D009293:Opioid-Related Disorders / Q000188:drug therapy / Q000503:physiopathology*; D011597:Psychomotor Performance / Q000187:drug effects / Q000502:physiology; D011743:Pyrimidines / Q000494:pharmacology; D011758:Pyrroles / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D018019:Receptors, Corticotropin-Releasing Hormone / Q000037:antagonists & inhibitors / Q000378:metabolism*; D055502:Secondary Prevention; D013312:Stress, Physiological / Q000188:drug therapy / Q000503:physiopathology*; D000099052:CRF Receptor, Type 1
chemical_list: C101628:CP 154526; C101531:CRF receptor type 2; D011743:Pyrimidines; D011758:Pyrroles; D018019:Receptors, Corticotropin-Releasing Hormone; D000099052:CRF Receptor, Type 1; D009020:Morphine; D003346:Corticotropin-Releasing Hormone